Mesoblast (ASX:MSB) reported Thursday a fiscal first-half loss of $0.042 per diluted share, compared with a loss of $0.0372 a year earlier.
Analysts surveyed by Visible Alpha expected a loss of $0.05.
Revenue for the six months ended Dec. 31, 2024, was $3.2 million, down from $3.4 million a year earlier. Analysts surveyed by Visible Alpha expected $3 million.
The board did not declare a dividend and "do not anticipate paying dividends in the foreseeable future," per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。